MDACC Study No:2011-0394 ( NCT No: NCT01456676)
Title:A single-arm dose-finding phase Ib multicenter study of the oral smoothened antagonist LDE225 in combination with nilotinib in chronic phase chronic myeloid leukemia patients who have failed prior therapy with other BCR-ABL tyrosine-kinase inhibitors
Principal Investigator:Jorge Cortes
Treatment Agent:LDE225; Nilotinib
Study Status:Terminated
Study Description:Unavailable
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:LDE225
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults